Clinical Ophthalmology (Sep 2019)
Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
Abstract
Arief Kartasasmita,1 Ohisa Harley2 1Departement of Ophthalmology, Universitas Padjadjaran/Cicendo Eye Hospital, Bandung, Indonesia; 2Netra Eye Hospital, Bandung, IndonesiaCorrespondence: Arief KartasasmitaDepartment of Ophthalmology, Universitas Padjadjaran, Jl. Cicendo No 4, Bandung 40141, IndonesiaTel +62 22 4231280Email [email protected]: To evaluate the difference in intravitreal bevacizumab (IVB) injection timing as adjuvant therapy to panretinal photocoagulation in patients with diabetic retinopathy combined with diabetic macular edema.Methods: This was a retrospective nonrandomized study. Forty eyes with severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) were divided into two groups; the IVB injection prior to, or after, panretinal photocoagulation. Changes in central macular thickness between the two groups were measured.Results: There was no significant difference in change in central macular thickness between two groups after treatment (p=0.66), neither in eyes with severe NPDR groups (p=0.48) nor eyes with PDR (p=0.82).Conclusion: IVB injection after panretinal photocoagulation gives insignificant difference in changes in central macular thickness with injection prior to laser treatment in patients with diabetic retinopathy combined with diabetic macular edema.Keywords: diabetic retinopathy, diabetic macular edema, bevacizumab, panretinal photocoagulation
